News

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)
Solid Biosciences' DMD gene therapy shows promise with SGT-003 and strong cash backing through 2027. Click here to read an ...
Managed Healthcare Executive1d
Capricor’s DMD Cell Therapy Faces FDA Setback
The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.
BioSpace2d
FDA Rejections: We Read 200 CRLs So You Don’t Have To
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
BioPharma Dive2d
FDA turns back Capricor’s Duchenne cell therapy
The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...
Asianet Newsable on MSN2d
Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy
The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does ...
BioSpace2d
Capricor Plunges on FDA Rejection of DMD Cell Therapy
In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy ...
The American Journal of Managed Care2d
TAS-205 Misses Primary End Point in Phase 3 DMD Trial
TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.
Capricor shares sink after US FDA declines approval for muscle disorder therapy
The U.S. Food and Drug Administration has declined to approve Capricor Therapeutics' cell therapy for a heart condition and ...
Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Pricing watchdog will take on the rising cost of drugs at launch
ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from ...
Investors Who Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
The Daily Reflector4d
Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ...
Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.